Data from a Completed Phase 1 Study to Assess the Safety, Tolerability and PK of ARRY-380 - an Oral Inhibitor of HER2

Array BioPharma

**Corresponding author:** Array BioPharma

**Categories:** Oncology

**Keywords:**

**How to cite this poster**

**Abstract**
ARRY-380 is a potent and selective oral small molecule inhibitor of HER2